Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu INRA Logo partenaire

Home page

Development of animal models for genetic diseases

Development of animal models for genetic diseases
Spontaneous models and diagnostic tests and Engineered models
  • Spontaneous models and diagnostic tests for genetic defects

Targeted industrial partners are the biotech companies providing genotyping services and /or biological models for medical applications (animal health and models for human health).
The development strategy of ANTAGENE estimates that the world market for diagnostic tests on genetic abnormalities in dogs will reach 50 millions euros in the coming 10 years. The market of diagnosis test in livestock is also expected to develop with the progress of genomics. Testing may become mandatory to check that a sire is free of a genetic defect before it can be used commercially. Diagnostic tests for several genetic abnormalities have already been patented:

- in dogs:

international patent 03116-01 for ichthyosis in the Golden retriever owned by CNRS (André et al., 2009) a European Patent n°08305372. 8 “Method for diagnosing and predicting cerebellar ataxia” owned by Alfort Nat. Vet School: Abitbol et al., 2008); International licences have been delivered to ANTAGENE for the marketing of the corresponding genetic tests for diagnostic and prediction; the income was 10 k€ in 2010.
 in pigs :patent PCT/EP2000/009896 on AMPK gene for meat quality and RN mutation, is owned at 40% by INRA and shared with two institutions from Sweden and Germany, income from the patent represents a total of 600 k€ for INRA since 2000.

- in cattle :

CVM is a genetic defect of the skeleton patented by a Danish institution, to which LABOGENA is returning 26 k€ each year for 2200 tests.

- in horses:

Equinom (Ireland) is marketing the ‘speed gene’ test, with a SNP in the myostatin gene associated with higher racing performance, at a price negociated between 500 and 1000 € according to number of samples.

The aim of CRB-Anim is to facilitate the molecular identification of genetic defects by research teams who will in turn decide about a patenting strategy. It is expected that several new mutations will be identified thanks to the genomic collections of CRB-Anim.
As observed with the Cani-DNA bioBank, a major economic return of the biobank is the use of samples to discover novel genes, novel protein and biological pathways in the field of veterinary research and breeding but also in the field of human medical research. For example, Oncovet Clinical Research is a French Contract Research Organisation interested in the dog models of the Cani-Dna biobank. The same situation can be encountered with livestock species and partners will share their know-how in the field of economic exploitation of results obtained from collections. For instance, the ANR Swan project is co-funded by pig breeders and is expected to identify causal mutations for congenital abnormalities.
Moreover, such tests can also be applied on frozen semen in order to characterize the stored semen before use. Those tests are particularly valuable for the breeding strategy. They can be used to avoid the birth of affected progeny by adapting crosses and taking care not to deplete the gene pool. Genetic tests will be proposed to breeding organisations, individual breeders and veterinarians.
Technical adjustments, new methods and novel development to perform genetic tests are also part of the outcomes. These developments will involve more particularly the private partners of CRB-Anim, ANTAGENE and LABOGENA which are willing to exploit the results by claiming licenses.

  • Engineered models

Animal models are being developed by research teams in other species than rodents. CRB-Anim will offer the possibility to store gametes, embryos or cells from such models for further by public or private laboratories. For instance, in fishes, a unique model has been developed in the rainbow trout to study sexual differentiation (Baron et al., 2007,2008) and rare homozygous clones are being produced (at INRA GABI) to study the relationship between genetics and environment such as nutrition (diet replacement with vegetal proteins) and temperature in a context of global warming (Quillet et al, 2007; Grima et al, 2008).

The ability to perform precise genetic engineering such as gene targeting for invalidation or surexpression, and allelic replacement in non rodent mammals would greatly benefit biomedical research by enabling, for example, the development of genetically defined rabbit models of human diseases. More than 10 years after the first demonstration, there are a few examples of gene targeting in mammals other than mice: COL1A1 in sheep [(McCreath et al., 2000], PRNP in sheep, cattle, and goats [Denning et al., 2001, Kuroiwa et al., 2004, Yu et al., 2006), GGTA1 in pigs (Dai et al., 2002, Lai et al., 2002), IGH in cattle (Kuroiwa et al., 2004) LIPH in rabbit (Diribarne et al., 2011), and CFTR in pigs (Rogers et al., 2008). Technological developments proposed by CRB-Anim on iPS and nuclear transfer are expected to facilitate the development of such models. INRA partner is currently working on a transgenic rabbit for the 8508 mutation of the CFTR gene in order to propose a model for testing new therapies against mucoviscidosis.